Knut Schäkel

10.0k total citations · 2 hit papers
103 papers, 5.4k citations indexed

About

Knut Schäkel is a scholar working on Immunology, Dermatology and Immunology and Allergy. According to data from OpenAlex, Knut Schäkel has authored 103 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Immunology, 28 papers in Dermatology and 15 papers in Immunology and Allergy. Recurrent topics in Knut Schäkel's work include Immunotherapy and Immune Responses (35 papers), Psoriasis: Treatment and Pathogenesis (27 papers) and T-cell and B-cell Immunology (27 papers). Knut Schäkel is often cited by papers focused on Immunotherapy and Immune Responses (35 papers), Psoriasis: Treatment and Pathogenesis (27 papers) and T-cell and B-cell Immunology (27 papers). Knut Schäkel collaborates with scholars based in Germany, United States and Switzerland. Knut Schäkel's co-authors include Adriana Rendón, Marc Schmitz, Gwendalyn J. Randolph, Guzman Sánchez‐Schmitz, E. Peter Rieber, Michael J. Meurer, Hridayesh Prakash, Michael Bachmann, Günter J. Hämmerling and Carmen Timke and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Knut Schäkel

98 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Psoriasis Pathogenesis and Treatment

2019 1.3k citations Knut Schäkel et al. profile →
Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy

2013 840 citations Knut Schäkel et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Knut Schäkel Germany	33	3.6k	1.2k	1.1k	823	492	103	5.4k
Jean‐Claude Lecron France	33	3.9k 1.1×	1.4k 1.2×	863 0.8×	1.3k 1.6×	809 1.6×	118	6.2k
Hiroyuki Yoneyama Japan	36	2.6k 0.7×	556 0.5×	1.0k 0.9×	795 1.0×	560 1.1×	85	4.9k
Curdin Conrad Switzerland	36	5.9k 1.6×	2.2k 1.8×	1.0k 0.9×	1.3k 1.5×	804 1.6×	108	7.5k
Menno A. de Rie Netherlands	33	2.6k 0.7×	2.1k 1.7×	566 0.5×	445 0.5×	327 0.7×	133	4.8k
Stephan Meller Germany	28	3.0k 0.8×	1.4k 1.2×	511 0.5×	749 0.9×	709 1.4×	70	4.8k
Percy Lehmann Germany	31	2.1k 0.6×	1.4k 1.2×	1.1k 1.1×	535 0.7×	296 0.6×	92	4.5k
Nobuyuki Onai Japan	31	4.0k 1.1×	443 0.4×	912 0.8×	1.0k 1.2×	469 1.0×	61	5.5k
Marcel B. M. Teunissen Netherlands	36	3.5k 1.0×	1.7k 1.4×	510 0.5×	544 0.7×	638 1.3×	85	4.8k
Vincent Ho Australia	32	1.3k 0.3×	1.8k 1.5×	1.3k 1.2×	1.1k 1.4×	363 0.7×	131	4.6k
Klemens Rappersberger Austria	32	1.6k 0.4×	558 0.5×	1.0k 0.9×	857 1.0×	254 0.5×	123	3.7k

Countries citing papers authored by Knut Schäkel

Since Specialization

Citations

This map shows the geographic impact of Knut Schäkel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Knut Schäkel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Knut Schäkel more than expected).

Fields of papers citing papers by Knut Schäkel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Knut Schäkel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Knut Schäkel. The network helps show where Knut Schäkel may publish in the future.

Co-authorship network of co-authors of Knut Schäkel

This figure shows the co-authorship network connecting the top 25 collaborators of Knut Schäkel. A scholar is included among the top collaborators of Knut Schäkel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Knut Schäkel. Knut Schäkel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schäkel, Knut, Kilian Eyerich, Andreas Pinter, et al.. (2025). 62281 GUIDE Phase 3b trial results: early intervention with guselkumab results in higher rates of fingernail psoriasis clearance and maintenance of nail response following treatment withdrawal. Journal of the American Academy of Dermatology. 93(3). AB215–AB215.

Schäkel, Knut, Khusru Asadullah, Andreas Pinter, et al.. (2024). 50236 GUIDE trial results after withdrawal in part 3: Long-term remission in patients with psoriasis treated with guselkumab within 15 months from onset of symptoms. Journal of the American Academy of Dermatology. 91(3). AB222–AB222. 1 indexed citations

Chen, Ye, Julianty Angsana, Nadine Krüger, et al.. (2024). LB943 Prediction of super response and drug-free disease control in guselkumab patients using multivariate baseline serum biomarkers: data from part 3 of GUIDE trial. Journal of Investigative Dermatology. 144(8). S165–S165. 1 indexed citations

Luft, Thomas, et al.. (2023). IFNγ Causes Keratinocyte Necroptosis in Acute Graft-Versus-Host Disease. Journal of Investigative Dermatology. 143(9). 1746–1756.e9. 7 indexed citations

Leipe, Jan, Renate Schmelz, Gabriela Riemekasten, et al.. (2023). Chronische Entzündungserkrankungen in Deutschland. Zeitschrift für Rheumatologie. 83(3). 200–209. 3 indexed citations

Forkel, Susann, Steffen Schubert, Guido Heine, et al.. (2023). Contact allergies to dental materials in patients. British Journal of Dermatology. 190(6). 895–903. 9 indexed citations

Thaçi, Diamant, Andreas Pinter, Michael Sebastian, et al.. (2023). Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS). British Journal of Dermatology. 191(1). 36–48. 1 indexed citations

Schäkel, Knut, Kristian Reich, K. Asadullah, et al.. (2023). Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study. Journal of the European Academy of Dermatology and Venereology. 37(10). 2016–2027. 46 indexed citations

Egeberg, Alexander, Joseph F. Merola, Knut Schäkel, et al.. (2023). Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes. Frontiers in Medicine. 9. 1092688–1092688. 2 indexed citations

10.

Jahraus, Beate, Beate Niesler, Emre Balta, et al.. (2022). Keratinocyte-induced costimulation of human T cells through CD6 - but not CD2 - activates mTOR and prevents oxidative stress. Frontiers in Immunology. 13. 1016112–1016112. 5 indexed citations

11.

Eyerich, Kilian, Peter Weisenseel, Andreas Pinter, et al.. (2021). IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 11(9). e049822–e049822. 54 indexed citations

12.

Sigurgeirsson, Bárður, Knut Schäkel, Chih-ho Hong, et al.. (2021). Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. Journal of Dermatological Treatment. 33(3). 1718–1726. 13 indexed citations

13.

Herster, Franziska, Zsofia Bittner, Nathan K. Archer, et al.. (2020). Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis. Nature Communications. 11(1). 105–105. 191 indexed citations

14.

Müller, Anne, Jessica Löffler, Philip Bucher, et al.. (2019). Keratinocyte-derived IκBζ drives psoriasis and associated systemic inflammation. JCI Insight. 4(22). 30 indexed citations

15.

Baran, Wojciech, Fareed Ahmad, Christina Alt, et al.. (2018). Phenotype, Function, and Mobilization of 6-Sulfo LacNAc-Expressing Monocytes in Atopic Dermatitis. Frontiers in Immunology. 9. 1352–1352. 10 indexed citations

16.

Fink, Christine, et al.. (2017). Quality of life, treatment satisfaction and efficacy of non-biological systemic therapies in patients with plaque psoriasis: study protocol for a prospective observational study. BMJ Open. 7(6). e014279–e014279. 1 indexed citations

17.

Magerl, Markus, M. Rother, Thomas Bieber, et al.. (2012). Randomized, double‐blind, placebo‐controlled study of safety and efficacy of miltefosine in antihistamine‐resistant chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology. 27(3). e363–9. 22 indexed citations

18.

Brignone, Chrystelle, Caroline Grygar, Manon Marcu, Knut Schäkel, & Frédéric Triebel. (2007). A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells. The Journal of Immunology. 179(6). 4202–4211. 60 indexed citations

19.

Schmitz, Marc, Senming Zhao, Yvonne Deuse, et al.. (2005). Tumoricidal Potential of Native Blood Dendritic Cells: Direct Tumor Cell Killing and Activation of NK Cell-Mediated Cytotoxicity. The Journal of Immunology. 174(7). 4127–4134. 68 indexed citations

20.

Schäkel, Knut, Reiji Kannagi, Bernhard Kniep, et al.. (2002). 6-Sulfo LacNAc, a Novel Carbohydrate Modification of PSGL-1, Defines an Inflammatory Type of Human Dendritic Cells. Immunity. 17(3). 289–301. 169 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact